Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

COVID-19: WHO awaits full clinical data on Merck’s antiviral pill

Chidinma Anyalewechi by Chidinma Anyalewechi
October 12, 2021
in Coronavirus
Australia to buy 300,000 Merck’s Covid-19 capsule as cases hit record high
Share on FacebookShare on TwitterShare on Linkedin

The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co. Inc to treat mild-to-moderate COVID-19 patients and reduce the rate of hospitalizations.

This was announced by a WHO spokesperson today, a day after the company said it had applied for U.S. emergency use authorisation, according to Reuters.

In response to questions asked at a U.N briefing in Geneva, the WHO spokesperson, Christian Lindmeier, said, “Indeed, this is an interesting development. We would have to see the full data about it. If it holds true, then it is another weapon in the fight against the COVID-19 pandemic.”

RelatedPosts

Why WHO declared Monkeypox outbreak a global health emergency

World Bank says COVID-19 sparked surge in financial inclusion globally

What this means

Molnupiravir, the pill produced by Merck & Co Inc, is expected to reduce the rate of hospitalisation and death from Covid-19 by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease.

However, Former U.S Commissioner for Foods and Drugs, Dr. Scott Gottlieb has explained why he’s optimistic about Merck’s Covid antiviral pill after the drugmaker applied for emergency use authorization to the Food and Drug Administration to treat people with mild to moderate Covid symptoms.

News continues after this ad


He says, “The topline data from this Merck study was probably the best treatment effect we’ve seen from orally available antiviral drug in the treatment of any respiratory pathogen, so this can make a real difference”.

The Merck pill is the first of its kind and if the emergency use authorization is given on the drug, it will be the first pill shown to work against Covid-19 and could be available to Americans by the end of the year.

News continues after this ad


Gottlieb commented on Merck’s pill, stating that it is part of an “overall, significant improvement in our therapeutic toolbox against this virus, not just with vaccines and therapeutics, but also with more accessible diagnostic tests.”

“We’ve seen sharp declines in the south, where delta’s largely run its course, so cases are coming down very sharply in populous states like Texas and Florida, but you’re seeing pretty dense epidemics in the midwest and plain states, and we still don’t know how the northeast and the northern states are going to fare,” he said.

He further predicts that a Covid-19 delta wave could hit northern U.S. states, despite the higher vaccination rates and higher prior infection rates.

Related

Tags: Covid-19MolnupiravirWHOWorld Health Organization

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

inq
avatrade
Stanbic bank
Mega Millions
UBN
Hot forex
Access Bank
Bankers Committee
First bank






    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • How to check 2022 WAEC result using SMS, online portal or serial number
    • Mark Zuckerberg says WhatsApp users can now exit groups unnoticed with new privacy features
    • Lafarge Africa H1 2022 earnings contracts by 37% despite growing demand for cement

    Follow us on social media:

    Recent News

    WASSCE 2020 records 65.24% credit pass in 5 subjects, including Mathematics and English

    How to check 2022 WAEC result using SMS, online portal or serial number

    August 9, 2022
    Mark Zuckerberg says WhatsApp users can now exit groups unnoticed with new privacy features

    Mark Zuckerberg says WhatsApp users can now exit groups unnoticed with new privacy features

    August 9, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com